Abstract
Several high throughput bioanalytic technologies, including next generation sequencing, proteomics, and mass spectrometry have seen increased clinical adoption. This trend is likely fueled by the need to more thoroughly characterize risk factors of disease and mechanisms of pathogenesis. and the opportunity to use this knowledge to tailor diagnosis, treatment and prevention of disease in ways that improve clinical outcomes. However, existing practice guidelines along with regulatory, and reimbursement paradigms continue to be predicated on biomarker paradigms that support testing of fewer analytes. The belief is that simpler biomarker disease association, like a drug-pharmacogene pair, are less costly in a randomized prospective clinical trial and in clinical practice. In this chapter we posit that the successful implementation of multianalyte diagnostic technology in the future is essential to realize the full potential of precision approaches in healthcare and to reduce marginal costs. As risk-sharing and outcomes-based payment models replace current reimbursement models for products and services, we predict a philosophical shift in the diagnostics, pharma, and payor industry towards business models that support multi-analyte testing and bioinformatics in clinical care.
Original language | English (US) |
---|---|
Title of host publication | Comprehensive Precision Medicine, First Edition, Volume 1-2 |
Publisher | Elsevier |
Pages | 221-237 |
Number of pages | 17 |
Volume | 1-2 |
ISBN (Electronic) | 9780128240106 |
DOIs | |
State | Published - 2024 |
Keywords
- Expression profiling
- Genotyping
- Laboratory developed tests
- Mass spectrometry
- Next generation sequencing
- Pharmacogenomics
- Proteomics
- Therapeutic drug monitoring
ASJC Scopus subject areas
- General Agricultural and Biological Sciences
- General Biochemistry, Genetics and Molecular Biology